C-Reactive Protein

Inhibition of the interleukin-6 mediated immune response with tolicizumab (Actemra, Genentech) vs. placebo in out-of-hospital cardiac arrest.

Rilonacept (Kiniksa Pharmaceuticals) as treatment for patients with recurrent pericarditis.

Tocilizumab, an interleukin-6 inhibitor, successfully reduced systemic inflammation and cardiac injury in resuscitated comatose patients with out-of-hospital cardiac arrest compared with placebo, according to results of the IMICA trial.

In patients with recurrent pericarditis, compared with placebo, rilonacept better resolved recurrent episodes and lowered risk for future episodes, according to data presented at the virtual American Heart Association Scientific Sessions.

Patients who have septic arthritis show significantly higher white blood cell count compared with patients who have gout, according to presented results.

Over 2 decades, various research and analyses have indicated that although residual LDL and inflammation are both associated with CV risk, they should be targeted individually for optimal outcomes in secondary prevention, a speaker said.

Erythrocyte sedimentation rate may not be a reliable indicator for timing of stage-two reimplantation for hip and knee arthroplasty, according to recently presented results.

A blood test to assess C-reactive protein levels in patients with COVID-19 may help determine who would benefit from treatment with glucocorticoid and who would not, according to a study published in the Journal of Hospital Medicine.

Adults with type 2 diabetes who undergo surgery need more insulin following surgery, particularly if they experience increased C-reactive protein level or HbA1c, according to findings published in the Journal of Diabetes Investigation.

Adults who take glucosamine supplements may be less likely to develop type 2 diabetes compared with those who do not take extra glucosamine, especially if they also have elevated levels of C-reactive protein, according to findings published in Diabetes Care.